- Home
- FORR vs NGNE Comparison
FORR vs NGNE Comparison
Compare FORR & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- NGNE
- Stock Information
- Founded
- FORR 1983
- NGNE 2003
- Country
- FORR United States
- NGNE United States
- Employees
- FORR N/A
- NGNE N/A
- Industry
- FORR Diversified Commercial Services
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- FORR Consumer Discretionary
- NGNE Health Care
- Exchange
- FORR Nasdaq
- NGNE Nasdaq
- Market Cap
- FORR 193.5M
- NGNE 213.2M
- IPO Year
- FORR 1996
- NGNE N/A
- Fundamental
- Price
- FORR $9.75
- NGNE $21.32
- Analyst Decision
- FORR
- NGNE Strong Buy
- Analyst Count
- FORR 0
- NGNE 7
- Target Price
- FORR N/A
- NGNE $41.86
- AVG Volume (30 Days)
- FORR 68.4K
- NGNE 223.5K
- Earning Date
- FORR 07-29-2025
- NGNE 08-08-2025
- Dividend Yield
- FORR N/A
- NGNE N/A
- EPS Growth
- FORR N/A
- NGNE N/A
- EPS
- FORR N/A
- NGNE N/A
- Revenue
- FORR $422,269,000.00
- NGNE $925,000.00
- Revenue This Year
- FORR N/A
- NGNE N/A
- Revenue Next Year
- FORR $2.04
- NGNE N/A
- P/E Ratio
- FORR N/A
- NGNE N/A
- Revenue Growth
- FORR N/A
- NGNE N/A
- 52 Week Low
- FORR $8.50
- NGNE $6.88
- 52 Week High
- FORR $20.62
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- FORR 45.09
- NGNE 61.90
- Support Level
- FORR $9.77
- NGNE $19.98
- Resistance Level
- FORR $11.00
- NGNE $18.21
- Average True Range (ATR)
- FORR 0.39
- NGNE 1.71
- MACD
- FORR -0.01
- NGNE 0.39
- Stochastic Oscillator
- FORR 28.21
- NGNE 90.54
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.